2014 Annual Meeting | 8MS.004 - Therapy of Epilepsy

Date Saturday 05/03/14

Time 06:30 AM - 08:00 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Morning Seminar

Director(s) Carl W. Bazil, MD, PhD, FAAN

Topic(s)

Learning Objectives Participants should have greater familiarity with the properties of currently available AEDs, including the newest agents; how to choose the best first drug; and additional issues for refractory patients. Drugs also have multiple formulations, including extended-release and generic equivalents; prescribers should be knowledgeable regarding optimal and safe use of these. The reasoning for early consideration of epilepsy surgery should be better understood, and participants should know how to identify and counsel the best candidates, in whom surgery is likely to be curative. Participants should also gain a better understanding of the management of pregnancy and status epilepticus.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge, Practice-based Learning and Improvement

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
06:30 AM - 07:00 AM		Sorting Through the AEDs: What's New and How to Choose? Brien J. Smith, MD, FAAN
07:00 AM - 07:30 AM		Formulas for Success: ER, XR, IV, Generic Carl W. Bazil, MD, PhD, FAAN
07:30 AM - 08:00 AM		Epilepsy Cases: Surgery? More Drugs? Devices?

Faculty Disclosures
Carl W. Bazil, MD, PhD, FAAN	Dr. Bazil has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medical Letter . Dr. Bazil has received publishing royalties from a publication relating to health care.
Brien J. Smith, MD, FAAN	Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma.